Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
IAS 2019: ViiV Healthcare showcasing innovation in HIV science
Data presented challenging the current treatment paradigm, investigating new options to meet the evolving needs of people living with HIV
-
GSK announces positive headline results in Phase 3 PRIMA study of ZEJULA (niraparib) for patients with ovarian cancer in the first line maintenance setting
Niraparib demonstrates significant improvement in progression free survival for women regardless of their biomarker status
-
ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with the 2-drug regimen Dovato (dolutegravir plus lamivudine) in virally suppressed patients switching from a TAF-containing, 3-drug regimen
Week 48 results from the TANGO study will be presented this month at 10th International AIDS Society Conference on HIV Science (IAS 2019).
-
ViiV Healthcare announces start of first-ever study to identify and evaluate approaches to implementing its once-monthly injectable HIV treatment in clinical practice
The long-acting injectable regimen has been granted Priority Review status by the FDA, with a target approval date set for December 29, 2019
-
GSK announces phase III start for its anti GM-CSF antibody, otilimab, in patients with rheumatoid arthritis (RA)
First phase III program in RA to include head-to-head comparisons with current treatments across all pivotal studies...
-
GSK joins forces with the University of California to advance genomic research and improve drug discovery
New ‘Laboratory for Genomics Research’ unites CRISPR pioneers with industry expertise to help unravel mysteries of the human genome
-
Nucala (mepolizumab) gains FDA approval for two new self-administration options
Nucala (mepolizumab) gains FDA approval for two new self-administration options
-
Nucala (mepolizumab) receives positive CHMP opinion for new self-administration options
Nucala (mepolizumab) receives positive CHMP opinion for new self-administration options
-
Save the Children Announces $1.5 Million Grant from GSK to Enhance Disaster Relief
GSK will donate $1.5 million over three years to help enhance the global nonprofit’s ability to respond to disasters in the United States.
-
GSK announces approval of Shingrix in China for prevention of shingles in adults aged 50 and over
National Medical Products Administration has approved Shingrix for the prevention of shingles (herpes zoster) in adults aged 50 or older.
-
GSK changes sales representative incentive program
We are announcing changes to our incentive program for sales representatives in certain countries.
-
GSK’s strong science prominent at ATS 2019
GSK will present more than 70 abstracts at the American Thoracic Society (ATS) International Conference 17-22 May, Dallas, US
-
GSK Science in the Summer™ Aims to Inspire Youth with STEM Learning through the ‘Science of Me’
Science in the Summer kicks off registration on May 13 and promises a one-of-a-kind science experience.
-
Phase III CAPTAIN study of Trelegy Ellipta in patients with asthma meets primary endpoint
Phase III CAPTAIN study of Trelegy Ellipta in patients with asthma meets primary endpoint
-
GSK delivers sales of £7.7 billion +6% AER, +5% CER
Total EPS 16.8p, +50% AER, +42% CER; Adjusted EPS 30.1p, +22% AER, +18% CER
-
ViiV Healthcare submits New Drug Application to US FDA for the first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine for treatment of HIV
If approved, cabotegravir and rilpivirine would be the first-ever long-acting, injectable treatment regimen for adults living with HIV
-
GSK receives US approval of Benlysta for intravenous use in children with lupus aged five years and above
FDA approval marks the first medicine in the US approved for children with systemic lupus erythematosus (SLE)
-
ViiV Healthcare announces CHMP Positive Opinion for Dovato® (dolutegravir/lamivudine) as a once-daily, single-pill, two-drug regimen for the treatment of HIV infection
ViiV Healthcare announces CHMP Positive Opinion for Dovato®
-
GSK invests $100 million to expand long-term vaccine manufacturing capabilities in Hamilton, MT
New investment in its manufacturing site in Hamilton, MT to expand the production capacity of key components of the adjuvant system
-
Eighty Philadelphia teachers to attend “Empowering STEM” on Monday, April 8th
Empowering STEM is full-day conference supporting teachers in tackling Philadelphia’s STEM career challenge.
